Oculis Holding AG - Ordinary shares (id:6584 OCS)
14.75 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 9:00:16 PM)
Exchange closed, opens in 12 hours 29 minutes
-0.34 USD (-0.34%)
0.27 USD (0.27%)
-1.54 USD (-1.54%)
25.85 USD (25.85%)
50.51 USD (50.51%)
51.91 USD (51.91%)
About Oculis Holding AG - Ordinary shares
Market Capitalization 629.35M
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
| Headquarters (address) |
Bahnhofstrasse 7 Zug 6300 Switzerland |
| Phone | 41 41 711 9325 |
| Website | https://oculis.com |
| Employees | 36 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | OCS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.60 - 18.00 |
| Market Capitalization | 629.35M |
| P/E trailing | 63.63 |
| P/E forward | -6.70 |
| Price/Sale | 725.05 |
| Price/Book | 6.61 |
| Beta | 0.008 |
| EPS | -1.59 |
| EPS Switzerland (ID:153, base:185) | 29.31 |